For the year ending 2025-12-31, CTKB made $201,493K in revenue. -$66,539K in net income. Net profit margin of -33.02%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue, net | 201,493 | 200,453 | ||
| Total cost of sales | 97,033 | 89,347 | ||
| Gross profit | 104,460 | 111,106 | ||
| Research and development | 36,468 | 39,402 | ||
| Sales and marketing | 49,440 | 49,114 | ||
| General and administrative | 58,936 | 43,113 | ||
| Total operating expenses | 144,844 | 131,629 | ||
| Loss from operations | -40,384 | -20,523 | ||
| Interest income (expense), net (notes 11, 12) | 474 | -5,239 | ||
| Interest income | 2,216 | 5,121 | ||
| Other income, net | 8,801 | 4,463 | ||
| Total other income, net | 10,543 | 14,823 | ||
| Loss before income taxes | -29,841 | -5,700 | ||
| Provision for (benefit from) income taxes | 36,698 | 320 | ||
| Net loss | -66,539 | -6,020 | ||
| Less net loss allocated to noncontrolling interests | 0 | - | ||
| Net (loss) income attributable to common stockholders, basic | - | -6,020 | ||
| Net loss attributable to common stockholders, diluted | -66,539 | - | ||
| Basic Average Shares | 127,745,939 | 130,611,330 | ||
| Diluted Average Shares | 127,745,939 | 130,611,330 | ||
Cytek Biosciences, Inc. (CTKB)
Cytek Biosciences, Inc. (CTKB)